Transdermal Skin Patches; a Medicated Patch That Can Deliver Drugs through Skin Portals Directly to the Bloodstream

Transdermal Skin Patches
Transdermal Skin Patches

Transdermal Skin Patches, also known as skin patch, is a medicated adhesive patch, which is placed on the skin to deliver regular doses of medication into the bloodstream through the skin. A transdermal patch provides a non-invasive method of drug delivery while allowing for a steady absorption of a drug over an extended period of time, providing an alternative delivery method. Transdermal patches provide a specific, predetermined dose of medication which is absorbed through the skin and into the bloodstream.

Transdermal Skin Patches are a method of drug delivery in which an adhesive patch provides a pre-prescribed dose of medication that is absorbed through the skin and into the bloodstream. The term ‘transdermal’ describes a delivery method used for administering pharmaceuticals. These patches are designed for short-term or long-term administration and can either be electronic or mechanical. It is a painless method of drug delivery, with the added benefit of providing a constant therapeutic dosage over a predetermined time period.

Although comparable to oral-dosage forms in efficacy, skin patches have several advantages over oral forms. Transdermal patches adhere to the skin as a way to deliver drugs. They provide non-invasive and painless method of drug delivery. It is modern technique of pain management designed to treat chronic pain and other conditions. Transdermal delivery systems have gained extensive attention due to the ease of administration. Transdermal Skin Patches Market are now widely used as cosmetic, topical, and transdermal delivery systems.

Currently, the use of transdermal drug delivery has increased due to improved bioavailability, reduced adverse events, reduced dosing frequency, and drug input termination at any point by the removal of the patch. In July 2018, Sumitomo Dainippon Pharma Co., Ltd. submitted a new drug application in Japan for a transdermal skin patch formulation of LONASEN, an atypical antipsychotic agent. While, in 2017, Medherant signed an agreement with a Japanese Company for Evaluation of Its TEPI patch drug delivery system.

Comments

Popular posts from this blog

Vehicle-To-Vehicle (V2V) Communication; Used To Wirelessly Interchange Data Regarding Their Speed, Place, And Heading

Global Polyphenol Market Is Expanding Owing To Growing Development Of Polyphenol-Rich Products For Health Improvement

Global Ferrous Sulfate Market Is Anticipated To Witness High Growth Due To Growing Demand In The Water Treatment Segment And Increasing Applications In Cement And Agriculture